About Assembly Biosciences, Inc.
https://www.assemblybio.comAssembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.
CEO
Jason A. Okazaki
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-02-12 | Reverse | 1:12 |
| 2014-07-14 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
GILEAD SCIENCES, INC.
Shares:4.51M
Value:$144.35M
FARALLON CAPITAL MANAGEMENT LLC
Shares:1.23M
Value:$39.33M
RA CAPITAL MANAGEMENT, L.P.
Shares:1.02M
Value:$32.69M
Summary
Showing Top 3 of 71
About Assembly Biosciences, Inc.
https://www.assemblybio.comAssembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $10.79M ▲ | $21.67M ▲ | $-9.2M ▲ | -85.23% ▲ | $-1.2 ▲ | $-9.16M ▲ |
| Q2-2025 | $9.63M ▲ | $4.59M ▼ | $-10.2M ▼ | -105.94% ▼ | $-1.33 ▼ | $-11.06M ▼ |
| Q1-2025 | $9.42M ▲ | $19.36M ▲ | $-8.82M ▲ | -93.62% ▲ | $-1.17 ▲ | $-9.91M ▲ |
| Q4-2024 | $7.36M ▲ | $4.61M ▼ | $-10.34M ▼ | -140.48% ▼ | $-1.72 ▼ | $-11.5M ▼ |
| Q3-2024 | $6.84M | $17.8M | $-9.61M | -140.44% | $-1.51 | $-10.92M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $232.56M ▲ | $240M ▲ | $57.3M ▼ | $182.69M ▲ |
| Q2-2025 | $74.98M ▼ | $80.78M ▼ | $62.68M ▼ | $18.1M ▼ |
| Q1-2025 | $91.03M ▼ | $99.02M ▼ | $71.88M ▼ | $27.13M ▼ |
| Q4-2024 | $112.08M ▲ | $119.17M ▲ | $85.81M ▲ | $33.36M ▲ |
| Q3-2024 | $94.95M | $100.26M | $74.26M | $26M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-9.2M ▲ | $-15.13M ▲ | $-158.27M ▼ | $171.93M ▲ | $-1.47M ▼ | $-15.18M ▲ |
| Q2-2025 | $-10.2M ▼ | $-16.76M ▲ | $16.99M ▲ | $357K ▼ | $593K ▲ | $-16.76M ▲ |
| Q1-2025 | $-8.82M ▲ | $-23.44M ▼ | $6.59M ▲ | $1.92M ▼ | $-14.93M ▼ | $-23.44M ▼ |
| Q4-2024 | $-10.34M ▼ | $-407K ▲ | $-6.7M ▼ | $17M ▲ | $9.89M ▲ | $-407K ▲ |
| Q3-2024 | $-9.61M | $-15.24M | $24.49M | $0 | $9.24M | $-15.24M |
CEO
Jason A. Okazaki
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-02-12 | Reverse | 1:12 |
| 2014-07-14 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
GILEAD SCIENCES, INC.
Shares:4.51M
Value:$144.35M
FARALLON CAPITAL MANAGEMENT LLC
Shares:1.23M
Value:$39.33M
RA CAPITAL MANAGEMENT, L.P.
Shares:1.02M
Value:$32.69M
Summary
Showing Top 3 of 71